Reaktionerne begyndte så tidligt som i uge 6 og så sent som i uge 55 i studiebehandlingen og optrådte under flere infusioner, men dog ikke altid i på hinanden følgende uger.
http://www.emea.europa.eu/

Reactions began as early as Week 6 and as late as Week 55 of study drug treatment, and occurred during multiple infusions though not always in consecutive weeks.
http://www.emea.europa.eu/

Hos 295 af de patienter, der blev behandlet med den anbefalede dosis på 0, 3 mg i 1 år (samlede antal injektioner = 2478, gennemsnitligt antal injektioner/patient = 8, 4) oplevede 84% af patienterne en bivirkning, som af investigatorerne blev tolket som værende relateret til injektionsproceduren, 3% af patienterne oplevede en alvorlig bivirkning, der muligvis var relateret til injektionsproceduren og 1% oplevede en bivirkning, der muligvis var relateret til injektionsproceduren, og som førte til afbrydelse eller ophør af studiebehandlingen.

In the 295 patients who were treated with the recommended dose of 0.3 mg for one year (total number of injections = 2478, mean number of injections/patient = 8.4) , 84% of the patients experienced an adverse event attributed by the investigators as being related to the injection procedure, 3% of the patients experienced a Serious Adverse Event potentially related to the injection procedure, and 1% experienced an adverse event potentially related to the injection procedure that led to study treatment discontinuation.

Af de patienter, der i løbet af studiet modtog studiebehandling, modtog 32, 2% (136/ 422) af patienterne 7- 12 administrationer af Avastin og 21, 1% (89/ 422) af patienterne modtog 13 eller flere administrationer af Avastin.
http://www.emea.europa.eu/

During the study, of the patients who received trial treatment, 32.2% (136/ 422) of patients received 7-12 administrations of Avastin and 21.1% (89/ 422) of patients received 13 or more administrations of Avastin.
http://www.emea.europa.eu/

Af de patienter, der i løbet af studiet modtog studiebehandling, modtog 32, 2% (136/422) af patienterne 7-12 administrationer af Avastin og 21, 1% (89/422) af patienterne modtog 13 eller flere administrationer af Avastin.

During the study, of the patients who received trial treatment, 32.2% (136/422) of patients received 7-12 administrations of Avastin and 21.1% (89/422) of patients received 13 or more administrations of Avastin.

Alle patienter fik studiebehandling som initial behandling for lokalt fremskreden eller metastatisk NSCLC, og patienterne i begge behandlingsgrupper fik fuldstændigt dækkende tilskud af folsyre og vitamin B 12.

All patients received study therapy as initial treatment for locally advanced or metastatic NSCLC and patients in both treatment groups were fully supplemented with folic acid and vitamin B12.